감염증 치료제 시장 : 시장 규모, 점유율, 성장 분석 - 유형별, 치료법별, 지역별 - 산업 예측(2024-2031년)

Global Infectious Disease Therapeutics Market size was valued at USD 116.8 billion in 2022 and is poised to grow from USD 121.71 billion in 2023 to USD 169.14 billion by 2031, growing at a CAGR of 4.2% during the forecast period (2024-2031).

The global healthcare sector continues to face immense challenges due to infectious diseases, which are triggered by a range of pathogens including viruses and bacteria. Despite progress in diagnostics, treatment methods, and preventive measures like vaccinations that have lowered mortality rates, the resurgence of these diseases remains a critical public health issue. Consequently, the infectious disease therapeutics market is poised for considerable growth, driven by rising infection rates, heightened awareness for early diagnosis, and increased funding for research from governmental and private entities. Nonetheless, the expensive nature of advanced treatments poses a challenge for market expansion, limiting access for many patients. Additionally, the growing preference for affordable generic medications threatens the growth of branded therapeutics aimed at combating infectious diseases.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Infectious Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Infectious Disease Therapeutics Market Segmental Analysis

Global Infectious Disease Therapeutics Market is segmented by type, treatment, end users and region. Based on type, the market is segmented into HIV, hepatitis, influenza, TB, malaria and HPV. Based on treatment, the market is segmented into antibacterial, antifungal drugs, antiviral drugs and others. Based on end users, the market is segmented into hospitals and clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Infectious Disease Therapeutics Market

The global infectious disease therapeutics market is likely to experience significant growth due to several driving factors. An increase in investment aimed at improving access to treatments for infectious diseases, along with strategic initiatives to raise awareness regarding both the treatments and diagnostics of these conditions, will contribute positively to market expansion. Furthermore, there has been a noticeable rise in clinical trial research dedicated to the development of innovative pharmaceutical solutions. Collectively, these elements are expected to propel the demand for infectious disease therapeutics, shaping a promising outlook for the market in the coming years.

Restraints in the Global Infectious Disease Therapeutics Market

The growth of the Global Infectious Disease Therapeutics market may be hindered by several factors, particularly the lack of awareness regarding available treatment options. In many developing nations, there is insufficient adoption of these therapies, compounded by limited reimbursement options for specific infectious diseases. This combination of inadequate understanding and accessibility can significantly restrain the market's expansion throughout the projected timeframe, as healthcare providers and patients may not fully utilize or access the innovative treatments necessary to combat these diseases effectively. Consequently, addressing these challenges is crucial for the market to reach its full potential in the coming years.

Market Trends of the Global Infectious Disease Therapeutics Market

The Global Infectious Disease Therapeutics market is witnessing significant growth, driven by the rising prevalence of malaria, particularly in developing regions such as India, Africa, and Southeast Asia. This surge is further fueled by increased research and development efforts from key pharmaceutical manufacturers and healthcare organizations aimed at advancing therapeutic options. Innovations in drug formulations and delivery methodologies, coupled with heightened awareness and funding for infectious disease management, are propelling the market forward. Additionally, strategic collaborations and partnerships in the healthcare sector are expected to enhance access to effective treatments, thereby shaping a robust market landscape in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies

Global Infectious Disease Therapeutics Market Size by Type & CAGR (2024-2031)

• Market Overview
• HIV
• Hepatitis
• Influenza
• TB
• Malaria
• HPV

Global Infectious Disease Therapeutics Market Size by Treatment & CAGR (2024-2031)

• Market Overview
• Antibacterial
• Antifungal Drugs
• Antiviral Drugs
• Others

Global Infectious Disease Therapeutics Market Size by End Users & CAGR (2024-2031)

• Market Overview
• Hospitals
• Clinics

Global Infectious Disease Therapeutics Market Size & CAGR (2024-2031)

• North America (Type, Treatment, End Users)
  • USA
  • Canada
• Europe (Type, Treatment, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, End Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Janssen Pharmaceuticals)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioCryst Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (BMS)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vir Biotechnology, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations